Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Dec;68(6):1190–1194. doi: 10.1038/bjc.1993.502

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.

T J Perren 1, E Wiltshaw 1, P Harper 1, M Slevin 1, R Stein 1, S Tan 1, M Gore 1, I J Fryatt 1, P R Blake 1
PMCID: PMC1968655  PMID: 8260372

Abstract

In a study designed to compare response rates of patients with stage III epithelial ovarian carcinoma to ifosfamide and carboplatin, 152 patients were randomised to receive either sequential therapy with three cycles of ifosfamide followed by three cycles of carboplatin, or to six cycles of single agent carboplatin. Ifosfamide was given every 3 weeks in a dose of 5 gm m-2 as a 24 h infusion with mesna, 1 gm m-2 by i.v. bolus prior to ifosfamide, 3 gm m-2 with ifosfamide, and 1 gm m-2 as an 8 h infusion after ifosfamide. Carboplatin was given in a dose of 400 mg m-2 by short i.v. infusion every 4 weeks. Sixty-eight evaluable patients were randomised to sequential ifosfamide/carboplatin, and 67 to single agent carboplatin. Median follow-up is 36 months (range 5.5-82.3). After three cycles of treatment two patients in the ifosfamide/carboplatin arm achieved complete remission (CR), and 12 partial remission (PR) for an overall response rate of 29%, whereas in the carboplatin arm ten patients achieved CR, and 23 PR, for an overall response rate of 63% (P = 0.0008). Seven of 15 patients with progressive disease, and nine of 20 patients with stable disease at the initial response evaluation, following three cycles of ifosfamide, subsequently responded to carboplatin therapy so that the final response rate to the complete regimen was 65% for the ifosfamide/carboplatin arm, compared to 71% for the carboplatin arm (NS). For the ifosfamide/carboplatin arm, median recurrence free survival and overall survival were 14.1 months and 18.7 months. Corresponding figures for the carboplatin arm were 14.5 months and 21.5 months (NS). Both treatments were generally well tolerated. However 47% of patients in the ifosfamide/carboplatin arm developed alopecia sufficient to require a wig, compared to only 2% in the carboplatin arm. Ifosfamide is clearly less effective, and more toxic than carboplatin. Ifosfamide failures can however be effectively salvaged by subsequent carboplatin treatment. Ifosfamide cannot be recommended for single agent therapy in ovarian carcinoma, however the combination of carboplatin plus ifosfamide might be a suitable treatment to be tested in a future randomised study against carboplatin alone.

Full text

PDF
1190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M., Kerby I. J., Rocker I., Evans A., Johansen K., Franks C. R. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol. 1989;28(1):57–60. doi: 10.3109/02841868909111182. [DOI] [PubMed] [Google Scholar]
  2. Brade W. P., Herdrich K., Varini M. Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1–47. doi: 10.1016/0305-7372(85)90011-8. [DOI] [PubMed] [Google Scholar]
  3. Bremner D. N., McCormick J. S., Thomson J. W. Clinical trial of isophosphamide (NSC-109724)--results and side effects. Cancer Chemother Rep. 1974 Nov-Dec;58(6):889–893. [PubMed] [Google Scholar]
  4. Bruckner H. W., Wallach R., Cohen C. J., Deppe G., Kabakow B., Ratner L., Holland J. F. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol. 1981 Aug;12(1):64–67. doi: 10.1016/0090-8258(81)90095-0. [DOI] [PubMed] [Google Scholar]
  5. Bryant B. M., Jarman M., Ford H. T., Smith I. E. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet. 1980 Sep 27;2(8196):657–659. doi: 10.1016/s0140-6736(80)92703-8. [DOI] [PubMed] [Google Scholar]
  6. Brühl P., Günther U., Hoefer-Janker H., Hüls W., Scheef W., Vahlensieck W. Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours. Int J Clin Pharmacol Biopharm. 1976 Jul;14(1):29–39. [PubMed] [Google Scholar]
  7. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  8. Evans B. D., Raju K. S., Calvert A. H., Harland S. J., Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983 Nov;67(11):997–1000. [PubMed] [Google Scholar]
  9. Gallagher C. J., Wiltshaw E., Coleman R. E., Harper P. G. A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. Cancer Chemother Pharmacol. 1989;24(1):54–57. doi: 10.1007/BF00254106. [DOI] [PubMed] [Google Scholar]
  10. Hardy J. R., Tan S., Fryatt I., Wiltshaw E. How nephrotoxic is carboplatin? Br J Cancer. 1990 Apr;61(4):644–644. doi: 10.1038/bjc.1990.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mangioni C., Bolis G., Pecorelli S., Bragman K., Epis A., Favalli G., Gambino A., Landoni F., Presti M., Torri W. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst. 1989 Oct 4;81(19):1464–1471. doi: 10.1093/jnci/81.19.1464. [DOI] [PubMed] [Google Scholar]
  12. Markman M., Hakes T., Reichman B., Lewis J. L., Jr, Rubin S., Jones W., Almadrones L., Pizzuto F., Hoskins W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol. 1992 Feb;10(2):243–248. doi: 10.1200/JCO.1992.10.2.243. [DOI] [PubMed] [Google Scholar]
  13. Omura G. A., Morrow C. P., Blessing J. A., Miller A., Buchsbaum H. J., Homesley H. D., Leone L. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983 Mar 1;51(5):783–789. doi: 10.1002/1097-0142(19830301)51:5<783::aid-cncr2820510506>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  14. Peto J., Easton D. Cancer treatment trials--past failures, current progress and future prospects. Cancer Surv. 1989;8(3):511–533. [PubMed] [Google Scholar]
  15. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schnitker J., Brock N., Burkert H., Fichtner E. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. Arzneimittelforschung. 1976;26(10):1783–1792. [PubMed] [Google Scholar]
  17. Sutton G. P., Blessing J. A., Photopulos G., Berman M. L., Homesley H. D. Gynecologic Oncology Group experience with ifosfamide. Semin Oncol. 1990 Apr;17(2 Suppl 4):6–10. [PubMed] [Google Scholar]
  18. Thigpen J. T., Blessing J. A., Vance R. B., Lambuth B. W. Chemotherapy in ovarian carcinoma: present role and future prospects. Semin Oncol. 1989 Aug;16(4 Suppl 6):58–65. [PubMed] [Google Scholar]
  19. Van Dyk J. J., Falkson H. C., Van der Merwe A. M., Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res. 1972 May;32(5):921–924. [PubMed] [Google Scholar]
  20. Williams C. J., Mead G. M., Macbeth F. R., Thompson J., Whitehouse J. M., MacDonald H., Harvey V. J., Slevin M. L., Lister T. A., Shepherd J. H. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol. 1985 Nov;3(11):1455–1462. doi: 10.1200/JCO.1985.3.11.1455. [DOI] [PubMed] [Google Scholar]
  21. Wiltshaw E., Evans B., Rustin G., Gilbey E., Baker J., Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol. 1986 May;4(5):722–729. doi: 10.1200/JCO.1986.4.5.722. [DOI] [PubMed] [Google Scholar]
  22. Wiltshaw E., Kroner T. Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep. 1976 Jan;60(1):55–60. [PubMed] [Google Scholar]
  23. Wiltshaw E., Subramarian S., Alexopoulos C., Barker G. H. Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1545–1548. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES